Skip to content

Baxter International BAX Estimated litigation liability

Estimated litigation liability at other companies

STERIS logo
STERISSTE
AbbVie logo
AbbVieABBV
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$10.27B-50.6%
Enterprise value$8.48B-55.6%
P/S0.9×-1.0×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:LitigationReserve.

The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's estimated litigation liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Baxter International's estimated litigation liability?
Baxter International (BAX) reported estimated litigation liability of $44M in Q1 2026.
How has Baxter International's estimated litigation liability changed year-over-year?
Baxter International's estimated litigation liability decreased by 4.3% year-over-year, from $46M to $44M.
What is the long-term trend for Baxter International's estimated litigation liability?
Over 5 years (2020 to 2025), Baxter International's estimated litigation liability has grown at a 3.3% compound annual growth rate (CAGR), from $40M to $47M.